Dmitry Balyasny’s Aquestive Therapeutics AQST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-744,536
Closed -$3.1M – 2999
2026
Q2
$3.1M Sell
744,536
-2,156,034
-74% -$9.07M ﹤0.01% 1606
2026
Q1
$12M Buy
2,900,570
+1,929,631
+199% +$7.83M 0.02% 953
2025
Q4
$6.27M Buy
+970,939
New +$6.05M 0.01% 1278
2024
Q4
– Sell
-28,937
Closed -$144K – 2701
2024
Q3
$144K Buy
+28,937
New +$113K ﹤0.01% 2610
2021
Q4
– Sell
-148,061
Closed -$646K – 2210
2021
Q3
$646K Buy
+148,061
New +$580K ﹤0.01% 1433

Other funds holding AQST

Dmitry Balyasny's AQST Position: Q3 2026 in Review

Dmitry Balyasny sold out of Aquestive Therapeutics (AQST) in Q3 2026, closing a stake of 744,536 shares — an estimated $3.1M sold.

Dmitry Balyasny first reported a position in AQST in Q3 2021 and held it in 5 quarters. The position peaked at $12M in Q1 2026. 190 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Dmitry Balyasny reported no remaining Aquestive Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 744,536 Aquestive Therapeutics shares in Q3 2026, an estimated $3.1M.
  • Dmitry Balyasny first reported a position in Aquestive Therapeutics in Q3 2021 and held it in 5 quarters.
  • Dmitry Balyasny's Aquestive Therapeutics position peaked at $12M in Q1 2026.
  • 190 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.